Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
124 results
  • Hypouricemia: what the practicing rheumatologist should know about this condition. [Review]
    Clin Rheumatol 2020; 39(1):135-147Pineda C, Soto-Fajardo C, … Sandoval H
  • We presented an update in the field of hypouricemia, which is defined as a serum urate concentration of < 2 mg/dL (119 μmol/L), for the practicing rheumatologist, who usually is the consulting physician in cases of disorders of urate metabolism. We performed a narrative review through a literature search for original and review articles in the field of human hypouricemia published between January…
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Gout Medications [BOOK]
    National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • Gout is a common metabolic disorder caused by high body uric acid levels, and marked by episodic deposition of uric acid crystals in joints (acute gouty arthritis) and other tissues such as the kidney (urate nephropathy or nephrolithiasis). The underlying condition appears to be an increase in total body uric acid stores and is usually marked by hyperuricemia. Hyperuricemia is typically defined a…
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Lesinurad [BOOK]
    National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • Lesinurad is a selective inhibitor of uric acid reabsorption which is used in combination with other agents in the therapy of gout. Lesinurad has had limited clinical use, but has not been associated with serum enzyme elevations during therapy or with instances of clinically apparent liver injury.
  • Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019). [Review]
    Expert Opin Ther Pat 2019; 29(11):871-879Dong Y, Zhao T, … Zhan P
  • Introduction: Human urate transporter 1 (URAT1), which is an influx transporter protein, is located at the apical surface of renal tubular cells and presumed to be the major transporter responsible for the reabsorption of urate from blood. About 90% of patients develop hyperuricemia due to insufficient urate excretion; thus, it is important to develop URAT1 inhibitors that could enhance renal urat…
  • Management of complex gout in clinical practice: Update on therapeutic approaches. [Review]
    Best Pract Res Clin Rheumatol 2018; 32(6):813-834Narang RK, Dalbeth N
  • Increasing therapeutic options are available for gout management. Anti-inflammatory agents are used in the acute management of gout flares, and interleukin-1 inhibitors are effective for those unable to take conventional anti-inflammatory treatments. Lowering of serum urate remains the cornerstone of effective long-term management. Allopurinol is the first-line urate-lowering therapy, and a gradu…
  • Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients. [Journal Article]
    Clin Rheumatol 2019; 38(12):3521-3528Presa M, Pérez-Ruiz F, Oyagüez I
  • CONCLUSIONS: Lesinurad plus allopurinol therapy compared with febuxostat seems an effective option for the management of hyperuricemia in patients who did not reach serum urate target to previous allopurinol monotherapy, associated to cost-savings for the Spanish Health System.Key Points• Lesinurad, in combination with allopurinol, has been recently authorized as second-line treatment of hyperuricemia in gout patients.• Lesinurad plus allopurinol provided higher effectiveness in terms of quality-adjusted-life-years (14.79) than febuxostat (14.69).• Lesinurad plus allopurinol resulted less costly (total cost/per patient) compared with febuxostat.• Lesinurad plus allopurinol resulted a dominant option compared with febuxostat.
  • Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. [Journal Article]
    J Pharmacol Exp Ther 2019; 371(1):162-170Taniguchi T, Ashizawa N, … Iwanaga T
  • The effect of dotinurad [(3,5-dichloro-4-hydroxyphenyl)(1,1-dioxo-1,2-dihydro-3H-1λ 6-1,3-benzothiazol-3-yl)methanone] was compared with that of commercially available uricosuric agents-namely, benzbromarone, lesinurad, and probenecid. Its effect on urate secretion transporters was evaluated using probe substrates for respective transporters. Dotinurad, benzbromarone, lesinurad, and probenecid in…
New Search Next